Authorization of bivalent COVID-19 boosters is based on scientific evidence of their safety and effectiveness

image credit The Johns Hopkins Bloomberg School of Publich Health SUMMARY In August 2022, the U.S. Food and Drug Administration (FDA) authorized bivalent COVID-19 vaccine formulations as single booster doses. These bivalent formulations contain messenger RNA (mRNA) from the original SARS-CoV-2 strain and mRNA present in the BA.4 and BA.5 lineages of the Omicron variant. Contrary to some viral claims online that these boosters weren’t adequately tested, the FDA based, Read More